Prosecution Insights
Last updated: November 11, 2026

Omniox Inc.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Omniox Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, there are 2 pending office actions in the portfolio. These actions are assigned to 2 distinct examiners and are located in 2 distinct art units, showing a distributed prosecution landscape.

The busiest examiner for the portfolio is CORDAS, EMILY ANN, who is responsible for 1 pending office action. With 2 pending office actions total and 2 distinct examiners, the current workload is divided equally. The involvement of 2 distinct art units indicates that the company's biotechnology applications are being processed across different specialized groups within the patent office. For the company, this means that its 2 pending office actions are subject to the different examination standards and technical focuses of 2 distinct art units and 2 different examiners. Managing 2 distinct examiners in 2 different art units for only 2 pending actions indicates a highly fragmented prosecution landscape for the company's current biotechnology filings.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
1
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (50%)
1
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (50%)
Multi-statute (no §101)1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CORDAS, EMILY ANN 1 51.0% +57.3%
FISCHER, JOSEPH 1 43.4% +45.6%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18684586 H-NOX PROTEINS FOR ORGAN PRESERVATION CORDAS, EMILY ANN —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18308203 MODULATION OF HYPOXIA ASSOCIATED WITH STROKE FISCHER, JOSEPH 71d
18684586 H-NOX PROTEINS FOR ORGAN PRESERVATION CORDAS, EMILY ANN —

Top Art Units

Art UnitApps
1632 1
1658 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18684586 H-NOX PROTEINS FOR ORGAN PRESERVATION CORDAS, EMILY ANN 1632 §102§103§112 Non-Final OA — Pending Feb 16, 2024
18308203 MODULATION OF HYPOXIA ASSOCIATED WITH STROKE FISCHER, JOSEPH 1658 §103Other Final Rejection 71d Pending Apr 27, 2023

Managing Omniox Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Omniox Inc. have?

Omniox Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Omniox Inc. applications?

Emily Ann Cordas has the most, with 1 of Omniox Inc.'s pending office actions.

What technology area are Omniox Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month